Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study
- Unidad de Cuidados Intensivos Cardiológicos. Hospital Universitario Central de Asturias, Spain
- Centro de Investigación Biomédica en Red (CIBER)-Enfermedades Respiratorias. Instituto de Salud Carlos III, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias, Spain
- Instituto Universitario de Oncología del Principado de Asturias, Spain
- Unidad de Cuidados Intensivos Polivalente. Hospital Universitario Central de Asturias, Spain
- Red de Investigación Renal (REDINREN), Spain
- Servicio de Inmunología. Hospital Universitario Central de Asturias, Spain
- Area de Gestión Clínica de Pediatría. Hospital Universitario Central de Asturias, Spain
- Department of Anesthesiology and Operative Intensive Care Medicine CCM/CVK, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Germany
- Servicio de Genética Molecular. Hospital Universitario Central de Asturias, Spain
- Servicio de Microbiología. Hospital Universitario Central de Asturias, Spain
- Universidad de Oviedo, Spain
- Servicio de Informática. Hospital Universitario Central de Asturias, Spain
- Critical Care Center, Hospital Universitari Parc Taulí, Institut D'Investigació I Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Spain
- Servicio de Bioquímica Clínica. Hospital Universitario Central de Asturias, Spain
Figures
Figure 1
Patient study flow chart.
From 250 patients admitted to the participant ICUs during the study period, 227 were included in the study and classified according to the IFIH1 rs1990760 variants and prescription of steroid …
Figure 2 with 3 supplements
Differences in gene expression according to IFIH1 rs1990760 genotypes.
(A) Expression of IFIH1 in peripheral blood in patients with CC/CT (n=31) and TT (n=11) variants (p-value calculated using a Wilcoxon test). (B) Heatmap showing expression of the 160 genes with …
Figure 2—figure supplement 1
IFIH1 expression per rs1990760 variants.
Figure 2—figure supplement 2
Gene networks involved in the regulation of the inflammatory response identified by Ingenuity Pathway Analysis among the genes with differential expression in patients with rs1990760 CC/CT and TT variants.
Figure 2—figure supplement 3
In-silico predictions of IFIH1 downregulation over a gene network involved in the regulation of the inflammatory response.
Figure 3 with 1 supplement
Differences in circulating cell populations according to IFIH1 rs1990760 variants (31 and 11 samples from patients with a CC/CT or TT variant, respectively).
Proportions of each cell line were estimated by deconvolution of RNAseq data. P-values were calculated using a Wilcoxon test and adjusted using the Benjamini-Hochberg method for a false discovery …
-
Figure 3—source data 1
Raw data used in Figure 3, showing different peripheral cell populations obtained after deconvolution of RNAseq data.
- https://cdn.elifesciences.org/articles/73012/elife-73012-fig3-data1-v1.csv
Figure 3—figure supplement 1
Correlation between measured and estimated (from deconvolution analysis) lymphocyte percentages in peripheral blood.
Figure 4 with 1 supplement
Differences in serum immune mediators according to IFIH1 rs1990760 variants (19 and 8 samples from patients with a CC/CT or TT variant, respectively).
P-values were calculated using a Wilcoxon test and adjusted using the Benjamini-Hochberg method for a false discovery rate of 5%. Points represent individual patient data. In boxplots, bold line …
-
Figure 4—source data 1
Raw data used in Figure 4, showing serum concentration of inflammatory mediators.
- https://cdn.elifesciences.org/articles/73012/elife-73012-fig4-data1-v1.csv
Figure 4—figure supplement 1
Serum inflammatory mediators in patients with a CC or CT variant in rs1990760 polymorphisms.
P-values were calculated using a Wilcoxon test and adjusted using the Benjamini-Hochberg method for a false discovery rate of 5%. Points represent individual patient data. In boxplots, bold line …
Figure 5 with 1 supplement
Expression of transcription factors STAT1 (A, p=0.012, no significant differences between variants in post hoc tests), STAT3 (B, p=0.443) and FOXO3 (C, p=0.002), and cytokine IL6 (D, p<0.001) induced by MDA5 activation using high molecular weight poly-I:C (a viral RNA analog) and dexamethasone in peripheral mononuclear blood cells.
Results were fitted using a mixed-effects linear model including cell donor as a fixed effect and experimental group and genotype as random effects. Pairwise p-values lower than 0.05 (using Holm’s …
-
Figure 5—source data 1
Raw data used in Figure 5, showing gene expression in an ex-vivo model of MDA5 stimulation.
- https://cdn.elifesciences.org/articles/73012/elife-73012-fig5-data1-v1.csv
Figure 5—figure supplement 1
Predicted effects of IFIH1 downregulation in absence (A) or in presence (B) of dexamethasone.
A number of molecules downregulated in response to lower IFIH1 expression are upregulated when dexamethasone is added (arrowheads).
Figure 6 with 1 supplement
Outcomes according to IFIH1 rs1990760 variants and treatment with dexamethasone.
(A) Cumulative incidence of ICU discharge alive and spontaneously breathing for each group. (B) Cumulative incidence of hospital death for each group. Outcomes were modeled as competing events. (C) …
Figure 6—figure supplement 1
Heatmaps with the differentially expressed genes in response to steroids in patients of each rs1990760 variant.
Transcriptomic signatures in each variant only share three genes.
Figure 7 with 1 supplement
In-silico clinical trials.
(A) Mortality curves modeled using data from the RECOVERY clinical trial, for each rs1990760 variant and treatment allocation, assuming a sample size of 500 patients per group. (B) Effect of …
Figure 7—figure supplement 1
Simulated survival curves corresponding to in-silico clinical trials testing dexamethasone in 6000 COVID-19 patients from populations with different allelic frequencies.
T allele frequencies correspond to an African/American/Asian population (0.13), mechanically ventilated sample of the RECOVERY trial (0.47), overall sample of the RECOVERY trial (0.53), and a White …
Tables
Table 1
Clinical characteristics of the study cohort.
COPD: Chronic Obstructive Pulmonary Disease. Values are shown as absolute count or median (interquartile range). PBW: Predicted body weight. NIV: Non-invasive ventilation. PEEP: Positive …
| rs1990760 | ||||
|---|---|---|---|---|
| Overall (n=227) | TT (n=65) | CC/CT (n=162) | p-value | |
| Demographics | ||||
| Age (years) | 67 (60–75) | 68.5 (63–75.25) | 66 (58–75) | 0.123 |
| Sex | ||||
| Male | 174 (77) | 47 (72) | 127 (78) | 0.327 |
| Female | 53 (23) | 18 (28) | 35 (22) | |
| Race | ||||
| Black | 3 (1.5) | 1 (2) | 2 (1.5) | 0.527 |
| White | 207 (91) | 62 (95) | 146 (90) | |
| Latino | 15 (7) | 2 (3) | 13 (8) | |
| Asian | 1 (0.5) | 0 | 1 (0.5) | |
| Body mass index (kg/m2) | 30 (27–33) | 30 (26–33) | 30 (27–32) | 0.592 |
| Days since symptom onset | 8 (6–11) | 8 (6–10) | 8 (6–11) | 0.873 |
| Days from hospital admission to ICU admission | 2 (1–4) | 2 (1–3) | 2 (1–4) | 0.841 |
| APACHE-II score | 15 (12–18) | 15.5 (13–18) | 14 (11—18) | 0.177 |
| Comorbidities | ||||
| Arterial hypertension | 132 (58) | 38 (59) | 94 (58) | 0.932 |
| Diabetes | 51 (23) | 14 (22) | 37 (23) | 1 |
| Chronic kidney disease | 15 (7) | 5 (8) | 10 (6) | 0.743 |
| COPD | 17 (8) | 7 (11) | 10 (6) | 0.339 |
| Cirrhosis | 2 (1) | 1 (2) | 1 (0.5) | 1 |
| Neoplasms | ||||
| No | 215 (95) | 62 (95)3 (5)0 | 154 (95) | 0.669 |
| Active | 10 (4) | 3 (5) | 7 (3.5) | |
| Past | 2 (1) | 0 | 2 (1.5) | |
| Immunosuppresive drugs (incl. steroids) | 5 (2) | 3 (5) | 2 (1.5) | 0.142 |
| Lung function at ICU admission | ||||
| Ventilation at admission | ||||
| Spontaneous /NIV | 38 (17) | 11 (17) | 27 (17) | 0.278 |
| Controlled invasive ventilation | 187 (82.5) | 53 (82) | 135 (83) | |
| Pressure support ventilation | 1 (0.5) | 1 (2) | 0 | |
| FiO2 | 0.5 (0.4–0.6) | 0.5 (0.4–0.7) | 0.5 (0.4–0.6) | 0.104 |
| PaO2/FiO2 (mmHg) | 204 (155–267) | 185 (142–226) | 218 (162–282) | 0.007 |
| PaCO2 (mmHg) | 43 (39–47) | 44 (39–47) | 43 (39–48) | 0.924 |
| Respiratory rate (min–1) | 18 (16–20) | 18 (16–20) | 18 (16–22) | 0.929 |
| Arterial pH | 7.38 (7.32–7.41) | 7.38 (7.33–7.42) | 7.37 (7.32–7.41) | 0.805 |
| Tidal volume/PBW (ml/Kg) | 7.6 (6.9–8.4) | 8 (6.9–9.2) | 7.5 (7–8.1) | 0.109 |
| Plateau pressure (cmH2O) | 24 (21–28) | 24 (22–29) | 24 (21–27) | 0.221 |
| PEEP (cmH2O) | 12 (10–14) | 12 (10–14) | 12 (10–14) | 0.397 |
| Driving pressure (cmH2O) | 12 (10–14) | 12 (10–14) | 12 (10–14) | 0.496 |
| Respiratory system compliance (ml/cmH2O) | 38 (32–50) | 36 (31–44) | 42 (32–50) | 0.11 |
| Laboratory results | ||||
| Leukocytes (×103/μl) | 8.34 (6.05–11.38) | 8.77 (5.96–11.52) | 8.29 (6.08–11.18) | 0.773 |
| Lymphocytes (×103/μl) | 0.65 (0.48–0.93) | 0.62 (0.47–0.94) | 0.67 (0.49–0.93) | 0.266 |
| Serum creatinine (mg/dl) | 0.83 (0.62–1.13) | 0.87 (0.62–1.14) | 0.82 (0.62–1.11) | 0.859 |
| Serum ferritin (ng/ml) | 1107 (717–1667) | 965 (634–1263) | 1262 (776–2374) | 0.011 |
| D-dimer (ng/ml) | 1053 (681–1967) | 1085 (643–1805) | 1036 (683–2126) | 0.854 |
| Additional treatments at ICU admission | ||||
| Steroids | 178 (78) | 51 (79) | 127 (78) | 1 |
| Vasoactive drugs | 102 (45) | 27 (42) | 75 (46) | 0.686 |
| Invasive mechanical ventilation | 210 (93) | 59 (91) | 151 (93) | 0.724 |
| Neuromuscular blocking agents | 99 (44) | 30 (46) | 69 (43) | 0.733* |
| Prone ventilation | 119 (52) | 32 (49) | 87 (54) | 0.657* |
| ECMO | 5 (2) | 2 (3) | 3 (2) | 0.544* |
Additional files
-
Supplementary file 1
Supplementary Tables.
1a. Primers and probes used to detect SARS-CoV-2. 1b: Primers used for qPCR of human genes. 1c: Clinical characteristics of patients according to IFIH1 rs1990760 genotypes and dexamethasone therapy. Values are shown as absolute count or median (interquartile range). PBW: Predicted body weight. NIV: Non-invasive ventilation. PEEP: Positive End-Expiratory Pressure. *p-values calculated for proportion over the number of intubated patients.
- https://cdn.elifesciences.org/articles/73012/elife-73012-supp1-v1.docx
-
Supplementary file 2
Results of differential expression analysis between rs1990760 variants.
- https://cdn.elifesciences.org/articles/73012/elife-73012-supp2-v1.csv
-
Supplementary file 3
Changes in gene expression after steroid treatment in rs1990760 variants.
- https://cdn.elifesciences.org/articles/73012/elife-73012-supp3-v1.csv
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/73012/elife-73012-transrepform1-v1.docx
-
Reporting standard 1
STROBE check list for cohort studies.
- https://cdn.elifesciences.org/articles/73012/elife-73012-repstand1-v1.doc
